NCT00077467View on ClinicalTrials.gov

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

March 31, 2006

Conditions

Blastic Phase Chronic Myelogenous LeukemiaChildhood Acute Promyelocytic Leukemia (M3)Recurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid Leukemia

Interventions

DRUG

bortezomib

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91006-3776

COG Phase I Consortium, Arcadia

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00077467 - Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia | Biotech Hunter | Biotech Hunter